The second general meeting of shareholders of ImmuneOnco was successfully held
On the morning of June 11, 2020, the second general meeting of shareholders of ImmuneOnco was held in the meeting room on the fifth floor, building 47, Lane 908, Ziping Road, which was newly completed. Dr. Tian Wenzhi, the founder and chairman of the company, attended the meeting with the company's senior management team. The company's directors, supervisors, shareholders and shareholders' representatives also attended the meeting.
The founder and chairman of ImmuneOnco, Dr. Tian Wenzhi, delivered a speech on the spot. He reviewed the company's development history and the achievements achieved in stages, summarized the work of the company in 2019, and introduced the new drug research and development, project promotion and other aspects in 2020. The management team of the company reports on the progress of clinical research, construction of technical platform, financial planning, business progress, etc.
After the meeting, there was also a warm exchange on the company's project progress, product R & D investment, precision medical layout and other directions, as well as the company's future development plan. At the same time, they expressed full confidence in the future development of the company and would support and pay attention to the development as always.
"Since its establishment in 2015, ImmuneOnco has adhered to the road of independent research and development and independent intellectual property rights of original new drugs. The company has developed rapidly. At present, there are two original new drug projects for clinical trial research, several of which are in preclinical research stage, and will gradually enter the stage of clinical trial research. Among them, the clinical trial of IMM01 project is progressing smoothly, and the preliminary research results are encouraging. We are looking forward to the follow-up clinical manifestations of IMM01. " Dr. Tian Wenzhi, founder and chairman of the company, said: "ImmuneOnco has been committed to building a new anti-tumor drug research and development technology platform with new immune regulation targets. I hope that in the near future, one after another of our original new drugs will be born. It not only benefits the patients, but also lives up to the trust and expectation of our shareholders. We will, as always, aim at the pain points and limitations of existing drugs, continue to plough deep into the field of anti-tumor, accelerate the pace of research and development, and develop high-quality biological drugs that can benefit cancer patients for a long time. "